RxSight Q2 revenue $33.6M (-4% YoY); net loss $(11.8)M; reaffirms FY2025 guidance

RxSight, Inc.

2025-Q2 EPS reported -$0.49 revenue$71,531,000

Total revenue $33.6M, down 4% from $34.9M in Q2 2024; LAL units up 13%, LDD units down 49%.
Net loss $(11.8)M ($(0.29)/share) vs $(6.1)M loss a year ago; adjusted net loss $(3.2)M.
Installed LDD base grew 34% to 1,084 units; FDA approved expanded LAL diopter range to -2.0 to +3.0.
Launched Light Adjustable Lens system in South Korea and Singapore; commercial team realigned.
Reaffirmed FY2025 revenue guidance $120M-$130M, gross margin 72%-74%, opex $145M-$155M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.